A Drug That Could Change Everything
Dordaviprone, a first-in-class small molecule therapy, is poised to fill a massive treatment gap. Radiation remains the primary option for patients with H3 K27M-mutant diffuse glioma, but dordaviprone could offer a much-needed breakthrough.
“If approved, dordaviprone has the potential to rapidly become the standard of care for a rare oncology disease,” said Jazz Chairman and CEO Bruce Cozadd. “We are eager to integrate it into our pipeline and bring this innovative treatment to patients who desperately need new options.”
The FDA has already granted priority review to dordaviprone’s New Drug Application (NDA), setting a Prescription Drug User Fee Act (PDUFA) action date for August 15. If given the green light, the drug could see a rapid U.S. commercial launch by late 2025.
Chimerix CEO: “A Global Opportunity”
For Chimerix, the acquisition represents years of cutting-edge research culminating in a global commercialization opportunity.
“We are excited to partner with Jazz Pharmaceuticals, a company with the scale and expertise to bring dordaviprone to more patients worldwide,” said Chimerix President and CEO Mike Andriole. “This deal is the culmination of years of scientific dedication, and it delivers both value to our shareholders and hope to patients.”
